Rovalpituzumab Tesirine (Rova-T) A DLL3 Target in SCLC - 102262


Rovalpituzumab Tesirine (Rova-T) A DLL3 Target in SCLC

Description: Charles Rudin, MD, PhD of Memorial Sloan Kettering Cancer Center discusses Rovalpituzumab Tesirine (Rova-T) a DLL3 target in SCLC. According to Dr. Rudin, Rova-T is an antibody drug conjugate that is directed to a cell surface target on small-cell lung cancer called DLL3. The drug directs attacks into the small-cell lung cancer cells, internalizes those molecules and releases the toxin inside the cell.

Initial Phase I of the study has already been completed which focus on small-cell lung cancer patients. Results show that 1/3 of patients are having an objective response to the drug. This will be a new biomarker and the target of this antibody drug conjugate is the DLL3 itself. Based on numbers, it is observed that patients with tumors cells of high DLL3 tend to respond very well compared to patients whose tumor cells didn’t show high level of activity or high level of expression.
Shared By : thoraciconcology
Posted on : 12/29/17
Added : 1 year ago